Dr. Srini Bandi
Obtained a B.Pharm, M.Pharm, and Ph.D. in Pharmaceutical Biotechnology. Joined Nacto Pharma Ltd. in 2002 as a Scientist on their Research and Development team. Involved in identifying market demand therapeutic biosimilar products and the development of upstream and downstream processes for the commercial production of therapeutic biomolecules from bacterial, yeast, and mammalian cell lines. Served a second year as a post-doctoral researcher in South Korea, and worked with Professor Yong-Keun Chang. Worked at the Korea Advanced Institute of Science and Technology in Taejon where he developed a deletion mutant strain of Actinosynnema sp., screened various nutritional factors, and optimized process parameters using statistical designs (DOE). Awarded an NSERC-VF-Postdoctoral Scholarship. Worked as a post-doctoral fellow with Dr. Susan Douglas at the IMB-NRC Institute in Canada from 2004-2007. Involved in a variety of different research projects and has published work in multiple scientific publications. Joined BioVectra Inc. in 2008 as a Scientist on the Research and Development team. Promoted to Manager of Biotech group in 2010. Promoted to Director in 2015. Involved in the process development, tech transfers of Biotech projects, troubleshoot of production issues, manufacturing and testing of GMP cell banks.